Boston Children’s Hospital has been granted a patent for compounds that inhibit the membrane proximal external region (MPER) of viral envelopes, specifically targeting HIV-1 and HIV-2 infections. The patent includes methods for treating or preventing these viral infections using the agent S2C3. GlobalData’s report on Boston Children’s Hospital gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Boston Children's Hospital, was a key innovation area identified from patents. Boston Children's Hospital's grant share as of July 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.